Published studies of exosome material applied to the skin surface, alone or after microneedling or laser, report mostly mild and short-lived effects such as redness, swelling and light crusting, and no serious adverse events [5, 10, 11]. The serious harms in the literature, including tissue necrosis and persistent nodules, followed injection of products, some of them sold for topical use, and those reports deserve their own heading [17, 18].
Coverage of exosome safety often places the two kinds of report side by side, which makes the topical picture hard to read. This guide separates them, gives the size of every study it cites, sets out the FDA position and the MedWatch reporting route, and ends with questions a patient can ask a provider.
Regulatory position
The FDA stated in its 2019 public safety notification that there are currently no FDA-approved exosome products, and its consumer alert, current on fda.gov as of 9 November 2026, says the same [1, 2]. ExaVeyra Sciences supplies exosome material for topical aesthetic use by licensed practitioners, applied to the skin surface, and describes it by its available formats. Whether any product suits a particular patient is a decision for that patient and their licensed provider.
Published topical studies report mild and short-lived reactions
The pooled evidence is consistent so far. Gaebe and colleagues reviewed 16 studies of vesicle products on the face in 2026, covering 503 participants, and reported that no serious adverse events were recorded [5]. They also rated the certainty of that evidence as low or very low and described the safety signal as short term, citing methodological limitations, inconsistent outcome assessment and short follow-up [5].
Wang, Bajwa and Rivers mapped 17 human studies in a 2026 scoping review and reported that adverse events were uncommon [6]. The granulomas, necrosis and allergic reactions they listed followed injection, and the authors named small samples, short follow-up, single-arm designs and potential conflicts of interest as limits on the whole literature [6].
Knauer and colleagues screened 2,394 records in 2026 and found 18 studies of topical exosomes for skin rejuvenation, only 8 of them with topical application alone. They reported that human studies of topical exosomes remain scarce [8], which is why each study below is described with its size and design.
Understanding exosome facial side effects after laser and microneedling
Most facial studies apply exosome material right after a procedure that opens small channels in the skin, so the reactions recorded belong partly to the procedure. The controlled studies compare one side of the face with the other, which lets the authors separate the two.
Kwon and colleagues ran a double-blind, randomized split-face trial of 25 patients in 2020 with exosome gel applied after each of three fractional CO2 laser sessions. They reported milder redness and shorter downtime on the exosome side than on the side that received a control gel [9].
Park GH and colleagues compared an exosome solution with saline after microneedling in 28 participants in 2023, across three sessions three weeks apart, and observed no serious adverse events [10]. Estupiñan, Ly and Goldberg compared topical exosome products with platelet-rich plasma after radiofrequency microneedling in 15 adults in 2025 and reported no adverse events; the expected transient mild pain, redness, swelling and light crusting resolved in less than one week [11].
| Study | Design and size | How the material was used | What the authors recorded |
|---|---|---|---|
| Kwon 2020 [9] | Double-blind, randomized split-face; n = 25 | Gel on the skin after fractional CO2 laser | Milder redness and shorter downtime on the exosome side |
| Park GH 2023 [10] | Randomized split-face against saline; n = 28 | Solution with microneedling | No serious adverse events observed |
| Estupiñan 2025 [11] | Investigator-blinded, non-randomized split-face against PRP; n = 15 | Topical after radiofrequency microneedling | No adverse events; expected pain, redness, swelling and crusting resolved in less than one week |
| Chandran 2025 [12] | Phase 1, open-label; n = 10 | Ointment on the forearm three times a day for 20 days | No product-related adverse events; no dryness, itch, redness or swelling |
| Wyles 2024 [13] | Single-arm, evaluator-blinded; n = 56 | Serum twice a day for 12 weeks, no procedure | No serious adverse effects |
| Park KY 2025 [17] | Case series; n = 4 | Injection of products sold for topical use, nonclinical setting | Persistent redness, nodules, granulomatous inflammation and scarring |
| AlBargawi 2025 [18] | Case report; n = 1 | Injection of freeze-dried exosomes | Findings consistent with ischemic necrosis of both cheeks three days later, then scarring |
Topical use on intact skin was well tolerated in the studies that tested it
A few studies left out the procedure entirely, which is the closest look at the material on intact skin. Chandran and colleagues ran a phase 1 study in 2025 in which 10 healthy adults applied an exosome ointment to the forearm three times a day for 20 days. They reported no product-related adverse events, no clinically significant laboratory changes, and no dryness, itch, redness or swelling where it was applied [12]. Four of the authors are employees of the company that developed the ointment [12].
Wyles and colleagues followed 56 adults who applied a platelet-derived extract serum twice a day for 12 weeks without any other aesthetic procedure, and reported no serious adverse effects in 2024 [13]. An earlier six-week study of the same product line by Proffer and colleagues, funded by the product’s maker, concluded the serum was well tolerated [14].
Granulomatous reactions after microneedling involve the topical product and the open channels
The rare reactions reported after microneedling with topical products are the reason to look closely at anything applied to opened skin. Friedmann and colleagues reviewed 13 publications describing 15 patients with granulomatous inflammation after microneedling in 2025, and reported that motorized pens and topical vitamin C were implicated in most cases [15].
Soltani-Arabshahi and colleagues described three women with facial granulomas after microneedling in 2014, two of whom had the same vitamin C serum applied during the procedure, and concluded that topical products applied before microneedling can introduce immunogenic particles into the dermis [16]. No exosome product was involved in either report, and both show why the full ingredient list of anything applied to opened skin belongs in the practice record.
Serious harms in the literature followed injection of products sold for topical use
The most severe reports sit outside topical use. Park KY described four women in 2025 who developed persistent redness, nodules, granulomatous inflammation and scarring after exosome-containing products were injected into the skin in a nonclinical setting. The author noted that such products are approved for topical use and that injecting them is off-label, and reported incomplete resolution in all four [17].
AlBargawi reported a 38-year-old man in 2025 with ulcerated papules and dusky discoloration on both cheeks three days after multiple injections of freeze-dried exosomes, consistent with ischemic necrosis that later left scarring. The author stated that no exosome product is approved for dermal injection [18].
These reports carry an important lesson for reading headlines: a harm recorded after injection describes a different route from a serum applied to the skin surface. ExaVeyra supplies exosome material for topical aesthetic use, and the route a practice chooses should match the product’s labeling.
Understanding the FDA safety notification on exosome products
The FDA issued a public safety notification in December 2019 reporting multiple serious adverse events in patients in Nebraska who received unapproved products marketed as containing exosomes. The same notice stated that there are currently no FDA-approved exosome products and asked health care professionals and consumers to report adverse events related to exosome products through MedWatch [1].
The agency’s consumer alert on regenerative medicine products, issued in July 2020 and last updated in April 2024, repeats that there are currently no FDA-approved exosome products and states that the FDA has authority to regulate exosome products [2]. It encourages anyone who had a bad side effect after such a product to report it to MedWatch [2]. Both pages remained posted with this wording when this guide was checked on 9 November 2026.
Reporting an adverse event through MedWatch keeps the record complete
MedWatch is the FDA’s medical product safety reporting program for health professionals, patients and consumers [3]. The 2019 notification points to the MedWatch Online Voluntary Reporting Form and states that a completed form can be submitted online or by fax to 1-800-FDA-0178 [1].
For products marketed as cosmetics, the FDA’s cosmetic complaint page lists reactions such as rash, redness, burn and irritation as reportable, and describes stopping use and contacting a healthcare provider as the first step. The page names Form FDA 3500 for health professionals and Form FDA 3500B for consumers, and states that MoCRA requires the responsible person for a cosmetic product to report serious adverse events to the FDA within 15 business days [4].
- Product name, manufacturer and lot number from the vial
- The date of the visit, and any procedure performed alongside the topical step
- Every other product applied to the area that day, with its ingredient list
- What the reaction looked like, when it started, and dated photographs
- How the practice was contacted, and the date a MedWatch report was filed
Understanding what the evidence does not yet show
The topical literature is encouraging and young, and its limits are specific enough to list. Each one is a reason documentation carries so much weight.
- Long-term safety: Gaebe 2026 described the safety signal as short term and named short follow-up as a limitation [5].
- Small samples: the controlled and open-label studies cited here enrolled between 10 and 56 participants [9, 10, 11, 12, 13].
- Low certainty: Gaebe 2026 rated the certainty of evidence low or very low, with risk of bias moderate to critical for most effectiveness outcomes [5].
- Product differences: Stack 2026 reported heterogeneous, nonstandardized protocols across 39 human studies, so a result for one product may not transfer to another [7].
- Thin product information: Knauer 2026 found minimal information on isolation, processing or shelf life among 20 commercial products [8].
- Industry ties: the Estupiñan 2025 site received a research grant from the product maker, Proffer 2022 was funded by its maker, and four Chandran 2025 authors work for the developer [11, 12, 14].
- Skin types and settings: the controlled and open-label studies cited here come from Korea, the United States and Singapore, and Estupiñan 2025 enrolled Fitzpatrick skin types I to IV only [9, 10, 11, 12, 13].
Questions to ask the provider before an exosome facial
A practice with good records can answer each of these with a document. The answers help a patient understand the specific product in front of them, which is the product the published studies cannot speak for.
- What is the source of this exosome material, and who manufactured it?
- What is the lot number, and may I see the certificate of analysis for that lot?
- How was it shipped and stored, and is the temperature record complete?
- How is the product labeled, and is it applied to the skin surface today?
- Which procedure, if any, comes before it, and what reactions are expected from that procedure on its own?
- What else will be applied to my skin during and after the visit?
- Whom do I contact if I notice a reaction, and will the practice help me file a MedWatch report?
Documentation keeps topical use transparent
Every question above has a paper answer, and ExaVeyra Sciences builds its exosome supply around those answers. Exosome material ships frozen from the manufacturing facility on dry ice, each lot carries its lot number, and a certificate of analysis is generated for every lot and available on request, together with the characterization panel and cold-chain records. Every ExaVeyra certificate reports serological testing for pathogens, and qualifying accounts can request ExaVeyra’s miRNA characterization data.
As the research grows, practices that keep clear records and patients who ask clear questions build a better safety picture for everyone. Readers looking for a provider can start with the practitioner directory. Anyone can ask the scientific team a question or apply without an NPI, and NPI verification unlocks the practitioner portal, exclusive resources and pricing, so a practice that wants to carry these products can apply for a verified account today.
Aviso Educativo: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
Referencias
- 1.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the agency statement that there are currently no FDA-approved exosome products, its report of multiple serious adverse events in patients in Nebraska who received unapproved products marketed as containing exosomes, and its request that health care professionals and consumers report adverse events related to exosome products through the MedWatch Online Voluntary Reporting Form or by fax.
- 2.U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. Issued July 22, 2020; content current as of 04/09/2024; verified 9 November 2026. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomesAgency consumer alert (CBER). Carries in this article: the FDA states it has authority to regulate exosome products, that there are currently no FDA-approved exosome products, and that anyone who had a bad side effect after a product presented as regenerative medicine is encouraged to report it to MedWatch.
- 3.U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Content current as of 11/03/2026; verified 9 November 2026. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-programAgency program page. Carries in this article: MedWatch is the FDA medical product safety reporting program for health professionals, patients and consumers, the route both FDA exosome notices point to.
- 4.U.S. Food and Drug Administration. How to Report a Cosmetic Product Related Complaint. Content current as of 10/05/2026; verified 9 November 2026. https://www.fda.gov/cosmetics/cosmetics-compliance-enforcement/how-report-cosmetic-related-complaintAgency reporting page for cosmetic products. Carries in this article: the FDA lists reactions such as rash, redness, burn and irritation as reportable, describes stopping use and contacting a healthcare provider as the first step, names Form FDA 3500 for health professionals and Form FDA 3500B for consumers, and states that MoCRA requires a responsible person to report serious adverse events for cosmetic products within 15 business days.
- 5.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk-of-bias and GRADE assessment, searches January 2000 to June 2025; 16 studies, 503 participants. Carries in this article: no serious adverse events were reported across the included studies, risk of bias was moderate to critical, GRADE certainty was low or very low, and the authors described the safety signal as short term with short follow-up. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
- 6.Wang OJE, Bajwa BB, Rivers JK. Exosome-Based Therapies in Dermatology: A Scoping Review. J Drugs Dermatol. 2026;25(4):368-376. PMID 41931695. doi:10.36849/jdd.9610Scoping review (PRISMA-ScR) including US and EU trial registries and grey literature; 17 human studies from 2020 to 2025. Carries in this article: the authors reported adverse events as uncommon and listed granulomas, necrosis and allergic reactions after injection; they named small samples, short follow-up, single-arm designs and potential conflicts of interest as limitations. Disclosure: no COI statement in the PubMed record.
- 7.Stack ER, Spongberg C, Braud SC, Stanton WN, Elway M. Clinical Advances in Exosome-Based Therapies for Aesthetic Medicine: A Systematic Review and Meta-analysis of Human Clinical Trials. Aesthet Surg J. 2026;46(12 Suppl 2):S13-S25. PMID 41800726. doi:10.1093/asj/sjaf178Systematic review and random-effects meta-analysis, searches to February 2025; 39 human studies. Carries in this article: the size of the human literature and the authors’ caution that heterogeneous, nonstandardized protocols limit how far results generalize. Disclosure: published in a journal supplement on exosomes; the PubMed record carries no funding or COI statement.
- 8.Knauer G, Chang A, Gupta A, Brownstone N, Mejia N, Bauman S, et al. Clinical Evidence and Commercial Landscape of Topical Exosomes for Skin Rejuvenation: A Scoping Review. Aesthet Surg J. 2026;46(11):NP148-NP157. PMID 42411735. doi:10.1093/asj/sjag141Scoping review with a librarian-reviewed search (2,394 records screened) plus a survey of the first 20 commercial exosome products in an online shopping search; 18 studies of topical exosomes for skin rejuvenation, with human and plant-derived exosome sources, 8 with topical application alone and 10 with a delivery device. Carries in this article: the authors reported that human studies of topical exosomes remain scarce and that commercial products carried minimal information on isolation, processing or shelf life. Disclosure: no COI statement in the PubMed record.
- 9.Kwon HH, Yang SH, Lee J, Park BC, Park KY, Jung JY, et al. Combination Treatment with Human Adipose Tissue Stem Cell-derived Exosomes and Fractional CO2 Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study. Acta Derm Venereol. 2020;100(18):adv00310. PMID 33073298. PMC9309822. doi:10.2340/00015555-3666Prospective, double-blind, randomized, split-face trial over 12 weeks with three fractional CO2 laser sessions (Korea); n = 25. Carries in this article: the authors reported milder redness and shorter downtime on the side that received the exosome gel after each session. Disclosure: the authors declared no conflicts of interest.
- 10.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective, randomized, split-face comparative study over 12 weeks, three microneedling sessions three weeks apart, saline on the control side (Korea); n = 28. Carries in this article: the authors observed no serious adverse events. Disclosure: no COI statement in the PubMed record.
- 11.Estupiñan B, Ly K, Goldberg DJ. Adipose Mesenchymal Stem Cell-Derived Exosomes Versus Platelet-Rich Plasma Treatment for Photoaged Facial Skin: An Investigator-Blinded, Split-Face, Non-Inferiority Trial. J Cosmet Dermatol. 2025;24(5):e70208. PMID 40414798. PMC12104007. doi:10.1111/jocd.70208Investigator-blinded, non-randomized split-face trial at one US research center; three radiofrequency microneedling sessions with two topical exosome products from one manufacturer on one side and PRP on the other; Fitzpatrick skin types I to IV; n = 15 enrolled, 14 completed. Carries in this article: the authors reported no adverse events, and expected effects of transient mild pain, redness, swelling and light crusting that resolved in less than one week. Funding: supported in part by a research grant to the study site from the manufacturer of the exosome products and the device; the authors declared no conflicts of interest.
- 12.Chandran NS, Bhupendrabhai MN, Tan TT, Zhang B, Lim SK, Choo ABH, Lai RC. A phase 1, open-label study to determine safety and tolerability of the topical application of mesenchymal stem/stromal cell (MSC) exosome ointment to treat psoriasis in healthy volunteers. Cytotherapy. 2025;27(5):633-641. PMID 39918488. doi:10.1016/j.jcyt.2025.01.007Phase 1, open-label tolerability study in healthy adult volunteers; an exosome ointment applied to the forearm three times a day for 20 days (Singapore); n = 10. Carries in this article: the authors reported no serious or product-related adverse events, no clinically significant laboratory abnormality, and no dryness, itch, redness or swelling at the application site. Disclosure: four authors are employees of the company that developed the ointment.
- 13.Wyles SP, Proffer SL, Farris P, Randall L, Hillestad ML, Lupo MP, Behfar A. Effect of Topical Human Platelet Extract (HPE) for Facial Skin Rejuvenation: A Histological Study of Collagen and Elastin. J Drugs Dermatol. 2024;23(9):735-740. PMID 39231070. doi:10.36849/JDD.8162Prospective, single-arm, non-randomized, evaluator-blinded study of a platelet-derived extract serum applied twice a day for 12 weeks with no other aesthetic procedure; n = 56. Carries in this article: the authors reported no serious adverse effects and described the product as well tolerated. Disclosure: the PubMed record lists no affiliations or COI statement; two authors also wrote Proffer 2022, which the product maker funded.
- 14.Proffer SL, Paradise CR, DeGrazia E, Halaas Y, Durairaj KK, Somenek M, et al. Efficacy and Tolerability of Topical Platelet Exosomes for Skin Rejuvenation: Six-Week Results. Aesthet Surg J. 2022;42(10):1185-1193. PMID 35689936. doi:10.1093/asj/sjac149Prospective, single-arm, non-randomized longitudinal study of a topical platelet-derived exosome serum over six weeks; the abstract does not state enrollment. Carries in this article: the authors concluded the serum was well tolerated in topical use. Funding and affiliations: funded by the product maker (Europe PMC grant record), and two authors list the product maker as their affiliation.
- 15.Friedmann DP, Mehta E, Verma KK, Harris R. Granulomatous Reactions From Microneedling: A Systematic Review of the Literature. Dermatol Surg. 2025;51(3):263-266. PMID 39584690. doi:10.1097/DSS.0000000000004450Systematic review of Medline, Scopus, Google Scholar and Cochrane; 13 studies describing 15 patients aged 26 to 74 with granulomatous inflammation after microneedling. Carries in this article: the authors reported that motorized pens and topical vitamin C were implicated in most cases, that patch testing was rarely done, and concluded that these reactions are rare and may persist. No exosome product was involved.
- 16.Soltani-Arabshahi R, Wong JW, Duffy KL, Powell DL. Facial allergic granulomatous reaction and systemic hypersensitivity associated with microneedle therapy for skin rejuvenation. JAMA Dermatol. 2014;150(1):68-72. PMID 24258303. doi:10.1001/jamadermatol.2013.6955Case series; three women with facial granulomas after microneedling, two of whom had the same branded vitamin C serum applied during microneedling, both with a positive patch test to it (USA); n = 3. Carries in this article: the authors concluded that topical products applied before microneedling can introduce immunogenic particles into the dermis. No exosome product was involved.
- 17.Park KY. Adverse Reactions Following Intradermal Injection of Exosome-Based Formulations: A Case Series. J Cosmet Dermatol. 2025;24(10):e70520. PMID 41097876. PMC12528963. doi:10.1111/jocd.70520Case series; four adult women after injection into the skin of exosome-containing products in a nonclinical setting (South Korea); n = 4. Carries in this article: the author described such products as approved for topical use, with injection off-label, and reported persistent redness, nodules, granulomatous inflammation and scarring with incomplete resolution in all four. Disclosure: the author declared no conflicts of interest.
- 18.AlBargawi S. Necrosis Following Dermal Injection of Lyophilized Exosomes: A Case Report. J Cosmet Dermatol. 2025;24(8):e70387. PMID 40820962. PMC12359287. doi:10.1111/jocd.70387Case report; one 38-year-old man with ulcerated papules and dusky discoloration of both cheeks three days after multiple injections of freeze-dried exosomes into the skin (Saudi Arabia); n = 1. Carries in this article: the author reported ischemic necrosis followed by scarring, and stated that no exosome product is approved for dermal injection. Disclosure: the author declared no conflicts of interest.